<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
______________
Date of Report (Date of earliest event reported): November 28, 2000
CuraGen Corporation
(Exact name of registrant as specified in its charter)
Delaware 0-23223 06-1331400
---------------- ------------- ---------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
555 Long Wharf Drive, 11th Floor
New Haven, Connecticut 06511
--------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (203) 401-3330
__________________________________________
<PAGE>
ITEM 5. OTHER EVENTS.
On November 28, 2000, the Registrant publicly disseminated a press release
announcing that the Registrant and Abgenix, Inc. have entered into a restated
collaboration agreement to develop and commercialize genomics-based antibody
drugs using XenoMouse technology and the Registrant's suite of functional
genomic technologies. Under the terms of the agreement, the Registrant will
sell 1,441,442 shares of the Registrant's common stock at a purchase price of
$34.68 to Abgenix. In addition, all of the shares of the Registrant's common
stock owned by Abgenix, including shares previously purchased, will be subject
to a one-year lock-up agreement. The Registrant's press release is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit 99.1 - Press Release dated November 28, 2000.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CURAGEN CORPORATION
(Registrant)
Date: November 28, 2000 By: /s/ David Wurzer
-----------------
Executive Vice President and
Chief Financial Officer
3
